Table 3.
Epidemiological, clinical characteristics and (tumor)‐specific survival of renal transplant patients with de novo urological tumors
| Prostate carcinoma | Transitional cell carcinoma | Renal cell carcinoma | Germ cell carcinoma | All urological malignancies | |
|---|---|---|---|---|---|
| Male/female (patient numbers) | 11/0 | 12/8 | 19/6 | 2/0 | 44/14 |
| Age at renal transplantation (years) | 53.5 (58.0) ± 10.2† | 54.0 (53.5) ± 7.7 | 46.6 (49.0) ± 12.8 | 28.0 (28.0) ± 14.1 | 49.8 (52.0) ± 11.9 |
| Kidney from deceased donor/living donor (patient numbers) | 11/0 | 20/0 | 23/2 | 2/0 | 56/2 |
| Age at tumor diagnosis (years) | 61.3 (61.0) ± 5.0 | 59.9 (60.5) ± 6.5 | 55.7 (56.0) ± 11.9 | 38.5 (38.5) ± 17.7 | 57.6 (59.5) ± 10.1 |
| Hemodialysis/peritoneal dialysis (patient numbers) | 11/0 | 18/2 | 25/0 | 2/0 | 56/2 |
| Duration of dialysis until renal transplantation (months) | 54.9 (60.0) ± 29.5 | 56.7 (49.5) ± 32.3 | 46.8 (43.0) ± 30.4 | 92.0 (92.0) ± 52.3 | 53.3 (49.5) ± 31.8 |
| Time period of tumor development after renal transplantation (months) | 72.6 (58.0) ± 84.1 | 83.5 (62.0) ± 67.8 | 107.6 (102.0) ± 61.1 | 60.5 (60.5) ± 37.5 | 95.4 (86.5) ± 67.3 |
| Tumor‐specific survival at 1‐/5‐year after cancer diagnosis (%) | 100.0/85.7 | 84.7/67.2 | 90.4/83.5 | 50.0/50.0 | 88.6/76.5 |
†Variables are presented as mean (median) ± standard deviation.